Samrat Pharma

{
  "main_header": {
    "sid": 116063,
    "name": "Samrat Pharma",
    "stock_name": "Samrat Pharma",
    "full_name": "Samrat Pharmachem Ltd",
    "name_url": "stocks-analysis/samrat-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "205.00",
    "chg": -3.8,
    "chgp": "-1.82%",
    "dir": -1,
    "prev_price": "208.80",
    "mcapval": "65.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530125,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE103E01016",
    "curr_date": "Jun 10, 03:30 PM",
    "curr_time": "19:54 PM",
    "last_traded_at": "Jun 10, 03:30 PM IST",
    "bse_nse_vol": "997 ",
    "exc_status": "Active",
    "traded_date": "Jun 10, 2026",
    "traded_date_str": "2026 06 10",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/samrat-pharma-116063-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Samrat Pharmachem Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-samrat-pharmachem-ltd-latest-results-good-or-bad-4027982",
        "imagepath": "",
        "date": "2026-06-01 19:22:21",
        "description": "Samrat Pharmachem Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported net sales of ₹71.77 crores, reflecting a modest year-on-year growth of 0.80% and a sequential increase of 13.15% from the previous quarter. However, this top-line growth is overshadowed by a substantial net loss of ₹2.04 crores, marking a severe decline in profitability compared to the same quarter last year.\n\nThe operating profit margin turned deeply negative at -1.73%, which is a notable deterioration from the positive margins recorded in previous years. This operational distress is further highlighted by the company's profit before tax, which fell to negative ₹1.87 crores, indicating a significant operational reversal. The PAT margin also collapsed to -2.84%, down from -0.56% in the prior year.\n\nThe financial performance indicates that while revenue has shown some growth, the compa..."
      },
      {
        "title": "Samrat Pharmachem Q4 FY26: Steep Losses Trigger 16% Stock Crash",
        "link": "https://www.marketsmojo.com/news/result-analysis/samrat-pharmachem-q4-fy26-steep-losses-trigger-16-stock-crash-4026745",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/SamratPharmache_quaterlyResult_4026745.png",
        "date": "2026-06-01 11:00:47",
        "description": "Samrat Pharmachem Limited reported a disastrous fourth quarter for FY2026, posting a net loss of ₹2.04 crores compared to a loss of ₹0.40 crores in the same quarter last year—a staggering deterioration of 410.00%. The micro-cap pharmaceutical chemicals manufacturer, with a market capitalisation of ₹65.00 crores, saw its stock plummet 15.63% to ₹210.00 on June 01, 2026, as investors reacted to the alarming financial performance that marked the company's worst quarterly showing in recent history."
      },
      {
        "title": "Samrat Pharmachem Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/samrat-pharmachem-ltd-is-rated-strong-sell-4019985",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SamratPharmache_mojoScore_4019985.png",
        "date": "2026-05-29 10:10:22",
        "description": "Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Aug 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 29 May 2026, providing investors with the latest insights into its performance and prospects."
      },
      {
        "title": "Samrat Pharmachem Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/samrat-pharmachem-ltd-is-rated-strong-sell-3996761",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SamratPharmache_mojoScore_3996761.png",
        "date": "2026-05-18 10:10:16",
        "description": "Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Aug 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 18 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Samrat Pharmachem Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/samrat-pharmachem-ltd-is-rated-strong-sell-3975795",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SamratPharmache_mojoScore_3975795.png",
        "date": "2026-05-05 10:10:17",
        "description": "Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Samrat Pharmachem Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/samrat-pharmachem-ltd-is-rated-strong-sell-3955845",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SamratPharmache_mojoScore_3955845.png",
        "date": "2026-04-21 10:10:18",
        "description": "Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Samrat Pharmachem Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/samrat-pharmachem-ltd-is-rated-strong-sell-3941496",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SamratPharmache_mojoScore_3941496.png",
        "date": "2026-04-10 10:10:24",
        "description": "Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Samrat Pharmachem Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/samrat-pharmachem-ltd-is-rated-strong-sell-3923788",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SamratPharmache_mojoScore_3923788.png",
        "date": "2026-03-30 10:10:17",
        "description": "Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 30 March 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Five Consecutive Losses Push Samrat Pharmachem Ltd to a New 52-Week Low",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/samrat-pharmachem-ltd-stock-hits-52-week-low-at-rs1944-3924033",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SamratPharmache_priceRelatedfactors_3924033.png",
        "date": "2026-03-30 09:53:39",
        "description": "For the fifth consecutive session, Samrat Pharmachem Ltd closed lower, hitting a fresh 52-week low of Rs 194.4 on 30 Mar 2026. This decline comes amid a broader market that has shown some resilience, underscoring the stock's persistent underperformance."
      }
    ],
    "total": 5753,
    "sid": "116063",
    "stock_news_url": "https://www.marketsmojo.com/news/samrat-pharmachem-116063"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "04-Jun-2026",
      "details": "Newspaper Publication of Extract of the Standalone Audited Financial Results for the year ended March 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Audited Financial Results For The Quarter And Year Ended 31 March 2026",
      "datetime": "30-May-2026",
      "details": "Audited Financial Results for the quarter and year ended 31st March 2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
      "datetime": "30-May-2026",
      "details": "The Board considered and adopted the financial results for the quarter and year ended March 31 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Samrat Pharmachem Ltd has declared <strong>10%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are Samrat Pharmachem Ltd latest results good or bad?

2026-06-01 19:22:21

Samrat Pharmachem Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported net sales of ₹71.77 crores, reflecting a modest year-on-year growth of 0.80% and a sequential increase of 13.15% from the previous quarter. However, this top-line growth is overshadowed by a substantial net loss of ₹2.04 crores, marking a severe decline in profitability compared to the same quarter last year. The operating profit margin turned deeply negative at -1.73%, which is a notable deterioration from the positive margins recorded in previous years. This operational distress is further highlighted by the company's profit before tax, which fell to negative ₹1.87 crores, indicating a significant operational reversal. The PAT margin also collapsed to -2.84%, down from -0.56% in the prior year. The financial performance indicates that while revenue has shown some growth, the compa...

Read full news article

Samrat Pharmachem Q4 FY26: Steep Losses Trigger 16% Stock Crash

2026-06-01 11:00:47

Samrat Pharmachem Limited reported a disastrous fourth quarter for FY2026, posting a net loss of ₹2.04 crores compared to a loss of ₹0.40 crores in the same quarter last year—a staggering deterioration of 410.00%. The micro-cap pharmaceutical chemicals manufacturer, with a market capitalisation of ₹65.00 crores, saw its stock plummet 15.63% to ₹210.00 on June 01, 2026, as investors reacted to the alarming financial performance that marked the company's worst quarterly showing in recent history.

Read full news article

Samrat Pharmachem Ltd is Rated Strong Sell

2026-05-29 10:10:22

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Aug 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 29 May 2026, providing investors with the latest insights into its performance and prospects.

Read full news article

Samrat Pharmachem Ltd is Rated Strong Sell

2026-05-18 10:10:16

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Aug 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 18 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Samrat Pharmachem Ltd is Rated Strong Sell

2026-05-05 10:10:17

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Samrat Pharmachem Ltd is Rated Strong Sell

2026-04-21 10:10:18

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Samrat Pharmachem Ltd is Rated Strong Sell

2026-04-10 10:10:24

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Samrat Pharmachem Ltd is Rated Strong Sell

2026-03-30 10:10:17

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 30 March 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Five Consecutive Losses Push Samrat Pharmachem Ltd to a New 52-Week Low

2026-03-30 09:53:39

For the fifth consecutive session, Samrat Pharmachem Ltd closed lower, hitting a fresh 52-week low of Rs 194.4 on 30 Mar 2026. This decline comes amid a broader market that has shown some resilience, underscoring the stock's persistent underperformance.

Read full news article

View All News